Abstract
Tocainide is a new antiarrhythmic agent that has recently been approved for oral use in the United States. The approved indication is treatment of symptomatic ventricular arrhythmias. It was developed from lidocaine in an attempt to overcome the disadvantages of this agent, namely, the low oral bioavailability, short half-life, and narrow therapeutic-toxic ratio.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Winkle RA, et al: Tocainide for drug resistant ventricular arrhythmias: efficacy, side effects, and lidocaine responsiveness for predicting tocainide success. Am Heart J 100:1031, 1980.
Almotrefi AA, Baker JBE: The antifibrillatory potency of aprindine, mexiletine, tocainide and lignocaine compared on Langendorff perfused hearts of rabbits and guinea-pigs. J Pharm Pharmacol 32:746, 1980.
Moore, et al: Electrophysiologic properties of a new antiarrhythmic drug: tocainide. Am J Cardiol 41:703, 1978.
Anderson JL, et al: Clinical electrophysiologic effects of tocainide. Circulation 57:685, 1978.
Horowitz LN, et al: Human electropharmacology of tocainide, a lignocaine congener. Am J Cardiol 42:276, 1978.
Morganroth J, et al: A review of the uses and limitations of tocainide: a class 1B antiarrhythmic agent. Am Heart J 110:856, 1985.
Ryden L, et al: Prophylaxis of ventricular tachyarrhythmias with intravenous and oral tocainide in patients with and recovering from acute myocardial infarction. Am Heart J 100:1006, 1980.
Haffajee CI, et al: Chronic tocainide therapy for refractory high-grade ventricular arrhythmias. Clin Cardiol 6:72, 1983.
Campbell RWF, et al: Oral tocainide in suspected acute myocardial infarction. Circulation 60:70, 1970.
Roden DM, et al: Tocainide therapy for refractory ventricular arrhythmias. Am Heart J 100:15, 1980.
Winkle RA, et al: Tocainide for drug resistant ventricular arrhythmias: efficacy, side effects, and lignocaine responsiveness for predicting tocainide success. Am Heart J 100:1031, 1980.
Maloney JD, et al: Open clinical studies at a referral centre: chronic maintenance tocainide therapy in patients with recurrent sustained ventricular tachycardia refractory to conventional antiarrhythmic agents. Am Heart J 100:1023, 1980.
Waleffe A, et al: Effects of tocainide studied with programmed electrical stimulation of the heart in patients with reentrant tachyarrhythmias. Am J Cardiol 43:292, 1979.
Keefe DL, et al: Prophylactic tocainide or lidocaine in acute myocardial infarction. Am J Cardiol 57:527, 1986.
Nyquist O, et al: Hemodynamic and antiarrhythmic effects of tocainide in patients with acute myocardial infarction. Am Heart J 100:1000, 1980.
Ryan WF, Karliner JS: Effects of tocainide on left ventricular performance at rest and during acute alterations in heart rate and systemic arterial pressure. Br Heart J 41:175, 1979.
Ikram H: Hemodynamic and electrophysiologic interactions between antiarrhythmic drugs and beta-blockers with special reference to tocainide. Am Heart J 100:1076, 1980.
Lalka D, et al: Kinetics of the oral antiarrhythmic lidocaine congener, tocainide. Clin Pharmacol Ther 19:757, 1976.
Craffner C, et al: Tocainide kinetics after intravenous and oral administration in healthy subjects and in patients with acute myocardial infarction. Clin Pharmacol Ther 27:64, 1980.
Elvin AT, et al: Tocainide kinetics and metabolism: effects of phenobarbitone and substrates for glucuronyl transferase. Clin Pharmacol Ther 27:652, 1980.
Ronfeld PA et al: Tocainide and metabolites: human pharmacokinetics and animal pharmacology. Clin Pharmacol Ther 27:282, 1980.
Woosley RL, et al: Suppression of ventricular ectopic depolarizations by tocainide. Circulation 56:980, 1977.
Winkle RA, et al: Clinical efficacy and pharmacokinetics of a new orally effective antiarrhythmic, tocainide. Circulation 54:884, 1976.
Weigers U: Pharmacokinetics of tocainide in patients with endstage renal failure. In: Pottage, Ryden L (eds) Workshop on tocainide: proceedings from a conference held in Copenhagen, 1979. AB Hassle, Moindal, Sweden, 1981, p 100.
Holmes B, et al: Tocainide: a review of its pharmacological properties and therapeutic efficacy. Drugs 26:93, 1983.
Mandai SK, Datta SK: Nodal bradycardia induced by tocainide. Postgrad Med J 59:262, 1983.
Engle TL, Le Winter M: Tocainide-induced ventricular fibrillation. Am Heart J 101:494, 1981.
Velebit V, et al: Aggravation and provocation of ventricular arrhythmias by antiarrhythmic drugs. Circulation 65:886, 1982.
Holt DW, et al: Dosage schedules for the transition from intravenous lignocaine to oral tocainide following acute myocardial infarction. Br J Clin Pharmacol 14:586P, 1982.
Author information
Authors and Affiliations
Rights and permissions
Copyright information
© 1988 Martinus Nijhoff Publishing, Boston
About this chapter
Cite this chapter
Schneeweiss, A., Schettler, G. (1988). Tocainide. In: Cardiovascular Drug Therapy in the Elderly. Developments in Cardiovascular Medicine, vol 72. Springer, Boston, MA. https://doi.org/10.1007/978-1-4613-2063-0_27
Download citation
DOI: https://doi.org/10.1007/978-1-4613-2063-0_27
Publisher Name: Springer, Boston, MA
Print ISBN: 978-1-4612-9225-8
Online ISBN: 978-1-4613-2063-0
eBook Packages: Springer Book Archive